On this page
What is Hepatitis C?
Hepatitis C is a viral infection caused by the hepatitis C virus (HCV). It primarily targets the liver, which is the body’s largest internal organ. The liver is responsible for digesting food, storing energy reserves, and detoxifying harmful substances from the blood.
HCV is transmitted through contact with infected blood. Common routes include:
- Sharing needles among people who inject drugs
- Accidental needlestick injuries in healthcare settings
- Less commonly, transmission can occur through sharing razors, accidental mucous membrane contact with infected blood, or, in rare cases, sexual intercourse.
The hepatitis C virus is unusually durable: it can survive outside the body at room temperature on surfaces for up to 3 weeks.
The incubation period ranges from 2 weeks to 6 months, and approximately 80% of patients experience no symptoms during this initial phase. When symptoms do appear, they may include fever, fatigue, loss of appetite, nausea, abdominal pain, dark urine, pale stools, joint pain, and jaundice.
What makes hepatitis C particularly dangerous is its silence: even in asymptomatic patients, the virus continues to replicate in the liver, triggering chronic inflammation that progresses invisibly for decades. Hepatitis C is a chronic disease. Without medical intervention, it does not resolve on its own, and its silent progression can eventually lead to cirrhosis, liver failure, and liver cancer.
There is currently no vaccine for hepatitis C. However, a highly effective pharmacological cure is now available that eradicates the virus from the body in over 95–98% of treated patients, representing one of the most significant advances in modern infectious disease medicine.
The HCV Virus
Hepatitis C develops when a person comes into contact with blood infected with HCV. The virus primarily enters and infects hepatocytes (liver cells), where it replicates using the cell’s own machinery.
Principal routes of exposure include:
- Blood transfusions and organ transplants before 1992: before universal blood screening for HCV was implemented, transfusions and transplants were a major transmission route. This risk has been virtually eliminated in developed countries since 1992.
- Sharing needles and injection equipment: the most frequent route of new infections today, particularly among people who inject drugs.
- Birth from an infected mother: a small percentage of infants born to HCV-positive mothers acquire the infection during delivery.
- Sexual contact: a rare route of transmission.
Risk Factors
The risk of HCV infection is higher if you:
- Are a healthcare worker with occupational exposure to blood
- Have injected drugs at any point in your life
- Are HIV-positive (HIV co-infection significantly increases HCV transmission risk)
- Have had a piercing or tattoo performed in unsanitary conditions with non-sterile equipment
- Received a blood transfusion or organ transplant before 1992
- Received clotting factor concentrates manufactured before 1987
- Have undergone long-term hemodialysis
- Were born to an HCV-positive mother
Contagion and Transmission
HCV is transmitted primarily through direct exposure to infected blood:
- Sharing used syringes: the dominant transmission route for new infections globally
- Blood donations and blood products (a risk now essentially eliminated in countries with mandatory screening)
- Needlestick injuries in healthcare settings
- Vertical (mother-to-child) transmission at birth if the mother is HCV-positive
Less commonly, transmission can occur through:
- Sexual intercourse with an infected partner (risk increases significantly in the presence of other sexually transmitted infections, anal sex, or when blood is present).
- Sharing personal items contaminated with infected blood, such as razors or toothbrushes, can pose serious health risks.
- Invasive healthcare procedures performed without adequate infection control (more commonly identified in outbreak settings).
Importantly: semen, saliva, and vaginal secretions are not infectious in terms of HCV transmission.
For patients with HCV who wish to have children: it is essential to consult your physician. While vertical transmission is uncommon, precautions are necessary. Avoiding sexual intercourse during menstruation is advisable, as HCV transmits more easily in menstrual blood.
Is There a Risk for Family Members or Housemates?
Transmission within a household is possible but, in practical terms, is rare and limited to situations involving direct exposure to the patient’s blood (CDC source).
For monogamous couples where one partner is HCV-positive, condom use is generally not considered mandatory. However, sexual intercourse during menstruation should be avoided, and barrier protection is recommended for any high-risk scenarios.
Never share razors, toothbrushes, nail clippers, or any personal care item that may carry traces of blood.
HCV is NOT transmitted through: sharing utensils or glasses, hugging, kissing, handshaking, coughing, or sneezing. Mosquitoes and other insects do NOT transmit HCV.
Symptoms
HCV infection is deceptively silent. In its initial phase, there are typically no symptoms at all. Approximately 2–3 out of 10 patients develop an acute phase 4–12 weeks after infection, with flu-like symptoms that may include:
- Mild fatigue
- Joint and muscle pain
- Nausea
- Loss of appetite
- Pain in the liver area
As the disease progresses to the chronic phase (which may last for decades), symptoms may remain absent or may include:
- Fatigue, often persistent and debilitating.
- Severe nausea and vomiting.
- Jaundice: yellowing of the skin and eyes.
- Fever (up to 38.8°C).
- Cognitive difficulties (“brain fog”).
- Mood changes and depression.
- Itching (pruritus).
- Digestive difficulties.
Only 15–25% of people clear HCV spontaneously without treatment. The remaining 75–85% develop chronic infection. Among those with chronic HCV:
- 60–70% will develop chronic liver disease
- 5–20% will develop cirrhosis within 20–30 years
- 1–5% will die from liver cancer or cirrhosis if untreated
This insidious progression, which often advances silently for years, means that HCV is frequently discovered incidentally during routine blood tests. By that time, significant liver damage may already have occurred.
Dangers and Complications
Chronic, untreated HCV infection can lead to serious and potentially fatal complications:
- Cirrhosis: after 20 to 30 years of chronic infection, extensive hepatic fibrosis may progress to cirrhosis. This condition involves irreversible scarring that disrupts liver architecture and function. As a result, complications such as portal hypertension, ascites, variceal bleeding, and eventually liver failure can develop.
- Liver cancer (hepatocellular carcinoma): chronic HCV is one of the leading causes of primary liver cancer globally. The risk is highest in patients who develop cirrhosis.
- Liver failure: in end-stage disease, the liver can no longer perform its essential functions, necessitating liver transplantation to survive.
- Extrahepatic manifestations: HCV can cause systemic complications including cryoglobulinemia (immune complex deposition in blood vessels), membranoproliferative glomerulonephritis (kidney disease), lymphoma, and metabolic disturbances.
Diagnosis
The modern HCV diagnostic pathway is rapid, accurate, and predominantly non-invasive. Early identification is critical to initiating treatment and preventing irreversible liver damage. Many countries have implemented national or targeted screening programs to identify people at increased risk of HCV infection.
Antibody Testing (HCV-Ab)
The first step is a simple blood test for HCV antibodies (HCV-Ab). A positive result indicates that the individual has been exposed to HCV at some point in their life. However, this test alone cannot distinguish between:
- A past infection that has been cleared (spontaneously or with treatment)
- An active, ongoing chronic infection
Confirmatory Molecular Test (HCV-RNA)
A positive antibody test must be followed by a molecular test detecting the virus’s genetic material in the blood (HCV-RNA). The presence of HCV-RNA confirms active infection. This test also quantifies the viral load, or the amount of virus circulating in the blood. This measurement guides treatment decisions and monitoring.
Liver Health Assessment
Once infection is confirmed, the physician assesses the extent of liver damage and the degree of fibrosis. Modern protocols rely almost exclusively on non-invasive methods, reserving liver biopsy for exceptional cases:
- Hepatic elastography (FibroScan): an ultrasound-based examination, completely painless, that measures liver stiffness. Greater stiffness correlates with greater fibrosis.
- Blood biomarkers: transaminases, platelet count, and calculated indices (APRI, FIB-4) provide additional information about liver health and help stage fibrosis.
- Abdominal ultrasound: evaluates liver structure, identifies signs of cirrhosis, and enables early detection of suspicious nodules through periodic surveillance.
Treatment and Therapy
Hepatitis C therapy has undergone a genuine revolution. The goal is no longer disease control but the complete, definitive eradication of the virus from the body. Hepatitis C is now considered curable in over 95 to 98% of treated patients, marking one of the most remarkable achievements in modern medicine.
Direct-Acting Antivirals (DAAs)
Modern DAA drugs have completely replaced the old interferon-based regimens. They work by blocking specific viral enzymes essential for HCV replication (NS3/4A protease, NS5A, and NS5B polymerase).
Key advantages of current DAA regimens:
- Oral administration: once-daily tablets, with no injections required.
- Short duration: typically 8 or 12 weeks of treatment.
- Excellent tolerability: side effects are generally mild (occasional headache or brief fatigue), a dramatic improvement over the severe adverse effects of interferon.
- Pangenotypic activity: the most widely used modern regimens (e.g., glecaprevir/pibrentasvir, sofosbuvir/velpatasvir) are effective against all major HCV genotypes (1–6), eliminating the need for genotype testing before treatment selection in most cases.
Goal of Treatment: Definitive Cure
The benchmark of cure is the Sustained Virologic Response (SVR), which is defined as undetectable HCV-RNA in the blood 12 weeks after completing treatment (SVR12). Once SVR12 is achieved:
- The virus is permanently eliminated from the body.
- The patient is no longer infectious.
- Liver inflammation stops progressing
- In many patients, fibrosis, even significant fibrosis, can gradually regress over time after viral clearance.
- The risk of cirrhosis, liver cancer, and liver failure is substantially reduced
Lifestyle and Practical Recommendations
Pharmacological treatment should be accompanied by protective lifestyle measures:
- Complete alcohol abstinence: alcohol dramatically accelerates hepatic fibrosis and HCC risk in HCV patients, and impairs the liver’s ability to heal after viral clearance.
- Healthy weight management: obesity and metabolic-associated steatotic liver disease (MASLD) compound HCV-related liver damage. Maintaining a healthy weight maximizes the liver’s regenerative capacity.
- Medication caution: many common medications, such as high-dose paracetamol (acetaminophen) and herbal products, are hepatotoxic or can interact with DAA therapy. St. John’s Wort, in particular, significantly reduces antiviral drug levels. Always consult your physician before taking any medication, supplement, or herbal remedy.
- Vaccinations: HCV-positive patients are strongly recommended to receive hepatitis A and hepatitis B vaccines to protect an already fragile liver from additional viral insults.
Managing Advanced Disease
In patients where HCV infection has already caused irreversible organ damage (end-stage liver failure), liver transplantation remains the only curative option. DAA therapy is now routinely administered before transplantation (to protect the new organ from reinfection) and, when needed, after transplantation.
Vaccine and Prevention
There is currently no vaccine against hepatitis C. Unlike hepatitis A and B, the high genetic variability of HCV (multiple genotypes and quasispecies) has so far prevented the development of an effective vaccine, though research is ongoing.
Vaccines do exist for hepatitis A and hepatitis B. If you have hepatitis C, your doctor may recommend vaccination against hepatitis A and B (if you are not already immune), as superinfection with either of these viruses on an already compromised liver can cause serious additional damage.
Primary prevention of HCV relies entirely on behavioral measures:
- Avoid sharing injection equipment: if you inject drugs, never share needles, syringes, spoons, or water. Needle exchange programs are a critical public health tool.
- Ensure sterile equipment for tattoos and piercings: choose licensed, reputable studios. Confirm that single-use, sterile needles and equipment are used.
- Practice safer sex: use condoms if you have multiple partners or are uncertain about your partner’s HCV status. For monogamous couples, sexual transmission risk is low but increases in the presence of other STIs, anal sex, or menstrual blood.
- Do not share personal care items: razors, nail clippers, and toothbrushes that may carry microscopic traces of blood should never be shared.
Frequently Asked Questions
What is hepatitis C?
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). It is a chronic disease in most infected individuals. Without treatment, it does not resolve on its own, and it can silently damage the liver for decades.
What are the symptoms?
In many cases, no symptoms appear until the disease is advanced and significant liver damage has already occurred. About 1 in 3–4 patients develop brief acute symptoms a few weeks after infection (fever, fatigue, loss of appetite, abdominal pain, nausea, jaundice). After this acute phase, the chronic infection may cause persistent fatigue, joint and muscle pain, cognitive difficulties, mood changes, pruritus, and digestive problems. These symptoms, however, often appear many years later.
How is hepatitis C transmitted?
HCV is contracted through contact with infected blood, most commonly through shared needles. Less commonly through:
- Sexual intercourse
- Sharing toothbrushes, razors, or other personal care items
- Tattoos or piercings performed with non-sterile equipment
- Mother-to-child transmission during birth
It is NOT transmitted through kissing, hugging, sharing utensils or glasses, or sharing toilet facilities.
How is it treated?
Modern Direct-Acting Antiviral (DAA) medications, taken as oral tablets once daily for 8–12 weeks, achieve complete viral eradication in over 95–98% of treated patients. Adopting a liver-protective lifestyle (no alcohol, healthy weight, no hepatotoxic substances) is equally essential to optimize recovery.
Is hepatitis C curable?
Yes. With modern DAA therapy, hepatitis C is definitively curable in the vast majority of patients. Once Sustained Virologic Response (SVR) is achieved, meaning HCV-RNA is undetectable at 12 weeks post-treatment, the virus is permanently eliminated.
Sources and Bibliography
- Mayo Clinic – Hepatitis C
- CDC – Centers for Disease Control and Prevention – Hepatitis C
- NIH / NIDDK – Hepatitis C
- NHS – Hepatitis C
- World Health Organization. Hepatitis C Fact Sheet. who.int
- European Association for the Study of the Liver (EASL). EASL Recommendations on Treatment of Hepatitis C: Final update of the series. J Hepatol. 2020;73(5):1170–1218.
- American Association for the Study of Liver Diseases (AASLD) / IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. hcvguidelines.org
